Seeking Clues to Teva Pharmaceutical Industries (TEVA) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics

Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining ...
Globes

Teva jumps ahead of Q3 results

The Israeli pharmaceutical company, managed by CEO Richard Francis, will publish its third quarter financial results on ...

Here's Why This Israeli Investment Giant Is Betting $834 Million on Teva Stock

Israel-based Phoenix Financial acquired more than 3.5 million additional shares of Teva Pharmaceuticals for an estimated $62.1 million in the third quarter. Post-transaction, the fund reported holding ...

Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis

This football season, Teva is increasing education around tardive dyskinesia (TD) by launching ‘The Other TD’ campaign TD is a chronic movement ...

Teva Agrees to Pay $35 Million to Settle Inhaler Antitrust Suit

Teva Pharmaceutical Industries Ltd. will pay $35 million to settle claims it delayed generic competition in the asthma inhaler market.
TipRanks on MSN

Teva launches ‘The Other TD’ disease education campaign

Pharmaceuticals announced the launch of ‘The Other TD,’ a disease education campaign leveraging the broad recognition of football ...
Investor's Business Daily on MSN

IBD Rating Upgrades: Teva Pharmaceutical ADR Flashes Improved Price Strength

A Relative Strength Rating upgrade for Teva Pharmaceutical ADR shows improving technical performance. Will it continue?